Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report

Glenn Tisman

Whittier Cancer Research, Whittier, CA, USA

ABSTRACT

Metastatic breast cancer to the liver is considered incurable. Though many patients with liver metastases may enjoy response to chemo-, immuno- and hormonal therapy, those so inflicted rarely remain disease-free from the time of diagnosis for longer than 6-11 months. New laboratory and clinical research identified that cross-talk between activation of the epidermal growth factor family of tyrosine kinase transduction pathways (EGF/HER2) and estrogen receptor (ER) activation plays a role in resistance to hormonal therapy.

A 59-year-old woman with a 4.5-cm invasive ductal, ER-positive/PR-negative, grade III adenocarcinoma of the breast was treated with mastectomy. Staging revealed biopsy-proven liver metastases. Surgery was immediately followed with vinorelbine, trastuzumab, tamoxifen and exemestane. The patient underwent a bone scan and PET/CT documented complete remission. She has remained in complete remission for 7 years.

It is proposed that a possible mechanism for prolonged remission of stage IV breast cancer in this patient may be related to suppression of EGF/HER2 by trastuzumab, thus inhibiting cross-talk-associated tamoxifen/estrogen withdrawal resistance.

Key words: cross-talk, epidermal growth factor, HER2, estrogen receptor, breast cancer, liver metastasis, trastuzumab, tamoxifen, exemestane.

Correspondence to: Glenn Tisman, MD, Whittier Cancer Research Building, 13025 Bailey Street, Suite A, Whittier, CA 90601, USA.
Tel +1-562-789-8822; e-mail glennmd@gmail.com

Received January 5, 2009; accepted February 17, 2009